Loading clinical trials...

MCI: CPAP Treatment of OSA (Memories2) | Clinical Trials | Clareo Health

ACTIVE_NOT_RECRUITINGNA

MCI: CPAP Treatment of OSA (Memories2)

Changing the Trajectory of Mild Cognitive Impairment With CPAP Treatment of Obstructive Sleep Apnea

NCT03113461•University of Pennsylvania

Summary

The purpose of this project is to determine whether obstructive sleep apnea (OSA) treatment with positive airway pressure therapy (CPAP) can delay the progression of cognitive impairment in patients with amnestic Mild Cognitive Impairment (MCI) as measured by cognitive testing, and brain magnetic resonance imaging (MRI) scans. Study participants will be assessed at baseline, six-month (cognitive tests only) and one-year follow-up.

Detailed Description

A growing number of research studies suggest that obstructive sleep apnea (OSA), characterized by episodic nocturnal collapse of the upper airway and reduction/cessation of breathing leading to significant nocturnal hypoxia, is associated with an increased risk of cognitive impairment. OSA is effectively treated with continuous positive airway pressure (CPAP), a pressurized nasal/face mask worn during sleep, but health care providers do not often prescribe it for Mild Cognitive Impairment (MCI) because there are no large, prospective research studies in this population confirming efficacy. This multi-site study will have a sample size of n=460 divided into three groups followed for one year: 1) a CPAP adherent group (approximately n=200); 2) two control groups consisting of 2a) a CPAP non-adherent control group (approximately n=160) and 2b) a no apnea control group (n=100). This will allow us to confirm whether CPAP treatment, controlling for risk factors such as neuroimaging findings and OSA severity at baseline, predicts the primary outcome of cognitive function at 1-year follow-up. Study participants will also undergo an Amyloid PET scan, use wearable activity monitors and functional/structural MRI brain scans. This research study will thus examine the one year effects of CPAP on cognitive function and elucidate physiological mechanisms for cognitive decline in aMCI and OSA.

Eligibility

Age

55 - 85 years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•1. age 55-85 years;
•2. moderate to severe OSA as defined by an AHI ≥ 15 events/hr, or no apnea defined by an AHI\<5 events/hr using American Academy of Sleep Medicine (AASM) diagnostic methodology as determined on a diagnostic polysomnography;
•3. Scoring education adjusted scores 28-35 (inclusive) on optional Telephone Interview for Cognitive Status Modified (pre-screen);
•4. Scoring 0-0.5 on the Clinical Dementia Rating Scale (CDR);
•5. Scoring 23-30 on the Mini Mental State Examination (MMSE) (exceptions may be made for participants with \<8 years of education as determined by the clinical research team);
•6. Memory impairment approximately 1.0-1.5 standard deviations below normal (adjusted for age and education) determined by scores on the Logical Memory II a test from the Wechsler memory scale;
•7. permitted medications (antidepressants, etc.) stable for at least 4 weeks (12 weeks for cholinesterase inhibitors/memantine) as per ADNI3 criteria;
•8. Non-depressed: Scoring \< 6 on the Geriatric Depression Scale;
•9. study partner, defined as an informant/caregiver who will be able to answer questions about the study participant, and meets one of the following criteria: (a) lives with the participant; (b) spends at least 3 times per week in-person contact with the participant; (c) spends at least 3 times per week in phone contact with the participant; or (d) spends at least 10 hours per week in any combination of phone or in person contact;
•10. adequate visual and auditory acuity to allow testing;
+4 more criteria

Exclusion Criteria

•1. any significant neurologic disease other than aMCI, such as Parkinson's Disease, Huntington's disease, normal pressure hydrocephalus, progressive supranuclear palsy, multiple sclerosis, head trauma followed by permanent neurologic deficits or known congenital brain structure abnormalities; within the past 6 months brain tumor, or seizure disorder, or subdural hematoma, or post-stroke (based on Modified Hachinski Ischemic Score);
•2. Optional: MRI exclusions - presence of pacemakers, aneurysm clips, artificial heart valves, ear implants, metal fragments or foreign objects in the eyes, skin, or body; however, the participant has the option of participating in the study without having an MRI;
•3. psychiatric disorders, including uncontrolled major depression, newly diagnosed or exacerbation in past 6 months of bipolar disorder as described in the DSM-IV, psychotic features, agitation or behavioral problems within the past 6 months that could lead to difficulty complying with the protocol, or history of schizophrenia (DSM-IV criteria);
•4. history of alcohol abuse or dependence within the past 6 months (DSM-IV criteria);
•5. any current significant systemic illness or unstable medical condition that could lead to difficulty in complying with the protocol (such as unstable cardiovascular disease); current use of supplemental oxygen or hypoxemia indicated by documented daytime oxyhemoglobin saturation \<90% on room air, uncontrolled thyroid disease (to be included must be on stable dose of thyroid medication for \>6 months), uncontrolled cirrhosis, cancer diagnosis within the past 6 months (exceptions may be made at the PI's discretion depending on cancer severity and the treatment required), clinically significant laboratory abnormalities such as reported untreated folate, B12, or TSH disease, or resident of a skilled nursing facility;
•6. participation in clinical studies involving neuropsychological measures being conducted more than twice a year;
•7. received and was adherent to CPAP or bi-level pressure for OSA within the past 6 months;

Locations (4)

Washington University in St. Louis

St Louis, Missouri, United States

University of Pennsylvania

Philadelphia, Pennsylvania, United States

University of Texas at Austin

Austin, Texas, United States

University of Virginia

Charlottesville, Virginia, United States

Key Dates

Start Date

January 19, 2018

Primary Completion Date

January 31, 2023

Completion Date

July 1, 2025

Last Updated

April 12, 2023

Enrollment

327

ACTUAL participants

Conditions

Mild Cognitive ImpairmentSleep Apnea, Obstructive

Interventions

CPAP

DEVICE

Sense4Safety Intervention

NCT07220668

Mild Cognitive Impairment

View study

RECRUITINGEARLY_PHASE1

Psilocybin for Depression in People With Mild Cognitive Impairment or Early Alzheimer's Disease

NCT04123314

Depressive SymptomsDepression+2 more

View study

RECRUITING

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: April 12, 2023Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

MCI: CPAP Treatment of OSA (Memories2)

Inclusion Criteria

Exclusion Criteria

Sense4Safety Intervention

Psilocybin for Depression in People With Mild Cognitive Impairment or Early Alzheimer's Disease

Validating the On-line Creyos Cognitive Assessment Platform in Older Adults With Major Depressive Disorder or Mild Cognitive Impairment

Effect of Striatal Temporal Interference Stimulation on Language Processing in Neurodegenerative Diseases

Maxillomandibular Advancement Surgery for Treatment of Obstructive Sleep Apnoea Syndrome

Feasibility Study of 'SuperBrain BOOM' for Mild Cognitive Impairment Patients